BioMarin struck a deal that could reach up to $475 million for HM15421/GC1134A (LA-GLA), a long-acting enzyme replacement therapy candidate for Fabry disease. The program combines Hanmi’s long-acting drug technology with GC Biopharma’s expertise in enzyme replacement therapies, aiming to extend exposure time with a subcutaneous route. Under the agreement, BioMarin received worldwide rights, while GC and Hanmi retain commercialization rights in Korea and take responsibility for regulatory approval efforts. GC and Hanmi remain eligible for development and commercial milestone payments plus tiered royalties on net sales, with milestones potentially totaling $405 million shared between the two South Korean firms. BioMarin said LA-GLA is being investigated in a Phase I/II trial (NCT06858397). Fabry disease is caused by mutations in the GLA gene and leads to progressive organ involvement including pain, kidney failure, and increased cardiovascular risk; GALAFOLD is an example of a disease-modifying option, while BioMarin positions LA-GLA as a new generation of Fabry therapy, potentially for a broader patient segment. The company framed the transaction as an expansion of its lysosomal portfolio following its acquisition of Amicus earlier in the year.